Hormone replacement therapy can triple the risk of breast cancer, the biggest ever study has found, following more than a decade of controversy.
Last year the National Institute of Health and Care Excellence(Nice) changed guidance to encourage more doctors to prescribe HRT claiming too many menopausal women had been left suffering in silence.
去年，国家卓越健康与护理研究所(The National Institute of Health and Care Excellence ) 修改指南，鼓励更多的医生在开出激素替代疗法时要声明许多更年期妇女都因此而留下默默忍受痛苦。
HRT is used to treat uncomfortable symptoms of the menopause– such as hot flushes, migraines, disrupted sleep, mood changes and depression – by topping up the decreased levels of hormones produced by the body.
But doctors were reluctant to prescribe it after a study in 2002 suggested it could raise the risk of cancer, a claim later widely disputed.
Now new findings by the Institute of Cancer Research and Breast Cancer Now suggest the original risk had actually been underestimated.
A study of 100,000 women over 40 years found those who took the combined oestrogen and progestogen pill for around five years were 2.7 times more likely to develop cancer compared to women who took nothing, or only the oestrogen pill.
The risk rose to 3.3 times for women who took the drugs for 15 yearsor more.
Around 14 in 1,000 women in their 50s are expected to develop breast cancer, but that rises to 34 in 1000 for women taking the combined pill, the study suggests.
“Our research shows that some previous studies are likely to have underestimated the risk of breast cancer with combined oestrogen-progestogen HRT,” said study leader Professor Anthony Swerdlow, of The Institute of Cancer Research.
“We found that current use of combined HRT increases the risk of breast cancer by up to threefold, depending on how long HRT has been used.
“Our findings provide further information to allow women to make informed decisions about the potential risks and benefits of HRT use.”
Women taking the oestrogen-only pill have no greater risk
HRT was first developed in the 1940s and was first made available to women in Britain in 1965.
However in 2002 the British Millennium Women Study published findings claiming that HRT raised the risk of cancer. Many doctors immediately withdrew prescriptions while the Medical Health care and Regulatory Agency (MHRA) issued new guidance recommending all womenbe given the "lowest effective dose should beused for the shortest time."
Since then the number of women taking HRT has more than halved with around one in 10 eligible patients now using thedrugs, approximately 150,000 women.
More recently a review by Imperial College and a 10-year studybyNew York University found no evidence of a link, adding further to the confusion and last year the National Institute for Health and Care Excellence (Nice) changed itsguidance to encourage doctors to offer HRT claiming one million women were suffering in silence.
At the time Nice said that the cancer risk was 27 in 1,000 so the new research, which followed 100,000 women for 40 years,increases that risk by 54 per cent.
The health watchdog said that the new study should not change how doctors prescribed HRT.
“We found that current use of combined HRT increases the risk of breast cancer by up to three fold, dependingon how long HRT has beenused” ----Professor Anthony Swerdlow, Institute of Cancer Research
Professor Mark Baker, director of the Centre for Guidelines at NICE,said: “As with Nice guidance this study recognisesthere is no increased risk of breast cancer with oestrogen-only HRT but the combined HRT can be associated with anincreased risk ofbreast cancer.
“The guideline makes clear that menopausal women should be informed that the impact of HRT on the risk of breastcancer varies with the type of HRT used.
“The message from our guidance to women isclear– talk about the menopause with your clinician ifyou need advice on your symptoms - it’s very important to discuss the options to find what might helpyou.”
The new study also found that the risk declined when women stopped taking HRT and there was no danger at all for women only taking oestrogen, which accounts for half of all prescriptions.
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “Whether to use HRT is an entirely personal choice, which is why it’s so important that women fully understand the risks and benefits and discuss them with their GP. We hope these findings will help anyone considering the treatment to make an even more informed decision.
“On balance, some women will feel HRT to be a necessity. But in order to minimise the risk of breast cancer during treatment, it is recommended that the lowest effective dose is used for the shortest possible time.
“The good news is that the increased risk of breast cancer begins to fall once you stopusing HRT.”